IBD and Biosimilars: What Healthcare Professionals Need to Know

IBD and Biosimilars: What Healthcare Professionals Need to Know

IBD and Biosimilars: What Healthcare Professionals Need to Know
RestartResume

Do you know how the approval of biosimilars will impact the treatment of inflammatory bowel disease? Hear from our experts and stay up to date!

Time to complete: 15 minutes

  • Overview

    As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.

  • Commercial Support

    This activity is supported by independent educational grants from Amgen, Boehringer Ingelheim, Coherus, Janssen, Organon, and Sandoz.

Register

We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free